Odyssey Therapeutics (ODTX) Gains 4.92% After Phase 2a Success; Shares Near Long‑Term Average
Odyssey Therapeutics’ OD‑001 Phase 2a trial shows strong efficacy for ulcerative colitis, driving a 4.92% stock rally near its 200‑day average.
- ODYSSEY THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read